The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients

NARecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 6, 2024

Primary Completion Date

December 5, 2025

Study Completion Date

December 5, 2025

Conditions

Chronic Hepatitis B

Interventions

DRUG

Sintilimab

100mg/10ml/1bottle

DRUG

Peg-IFNα-2b

180ug/0.5ml/1bottle

DRUG

NAs

tablets

Trial Locations (1)

RECRUITING

the Fifth Medical Center, Chinese PLA General Hospital, Beijing

All Listed Sponsors

lead

Beijing 302 Hospital

OTHER